– AnQlar™ had previously demonstrated antiviral activity against influenza and SARS-CoV-2 in three preclinical studies –
– FDA says Virpax can file an NDA request with the Office of Nonprescription Drugs –
BERWYN, Pennsylvania, USA, March 15, 2022–(COMMERCIAL WIRE)–virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company focused on the development of non-addictive product candidates for pain management, PTSD, CNS disorders and antiviral indications, has announced its exclusive license agreement for AnQlar™ with expanded Nanomerics Ltd. Virpax therefore has worldwide development and commercialization rights.
virpax has in vitro, ex-vivo (in human muscle cells) and liveComprehensive studies (in rats) on AnQlar, which found AnQlar to be more potent in inhibiting viral replication of SARS-CoV-2 and influenza in animals compared to human nares. No negative side effects were observed during the studies. Animal experiments also showed reduced viral load in animal brain tissue. Virpax plans to complete investigational new drug (IND) development studies in the fourth quarter of 2022 and plans to apply for non-prescription drug status.
“We would like to thank our partner Nanomerics for working with the company and revising our original agreement to exchange North American rights for an agreement that gives us global rights, as well as all commercial milestones and royalties against a profit sharing agreement. This will help us apply for OTC status for AnQlar with the FDA,” said Christopher M. Chipman, Chief Financial Officer and Secretary of Virpax.
“Acquiring the global rights to AnQlar is consistent with our global business model and positions the Company to enter into strategic partnerships or pursue commercial opportunities for this product candidate,” said Anthony P. Mack, Chairman and CEO of Virpax.
AnQlar (GCPQ) is a positively charged chitosan derivative that electrostatically binds to negatively charged viruses such as SARS-CoV-2 or influenza. AnQlar can prevent the coronavirus from attaching to the cell surface of the ACE-2 receptor, which acts as a mediator for virus infection. This molecule may have a double mechanism of action: virucidal properties and prevent the virus from entering the cell through the ACE-2 receptor.
AnQlar is a mucoadhesive polymer with a long nasal residence time. Application of AnQlar to the nasal mucosa can block viral infection by inhibiting viral attachment. provisional in vitro, ex-vivo and liveThe data shows that AnQlar inhibits SARS-CoV-2 replication and may inhibit virus spread and viral load in the brain.
Nanomerics Ltd is a specialist pharmaceutical company based in London, UK. Nanomerics is a spin-off from University College London and was formed to commercialize its biocompatible polymer technology for drug delivery and other applications. Nanomerics’ proprietary technology is based on world-leading knowledge and scientific leadership in polymer nanotechnology. Nanomerics creates unique patented and differentiated pharmaceutical active ingredients backed by high scientific quality. For example, the company’s Molecular Envelope Technology (MET) is a unique proprietary biocompatible polymer that represents a significant change in target tissue bioavailability. Nanomerics’ MET has won first prize in the British Royal Society of Chemistry’s Emerging Technologies competition. Co-founders and scientists, Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein, developed the technology at the University of Strathclyde and Glasgow and more recently at the UCL School of Pharmacy. Visit www.nanomerics.com for more information.
About Virpax Pharmaceuticals
Virpax is developing brand-name product candidates for pain therapies and non-addictive neurological disorders using its proprietary technologies aimed at drug delivery and drug delivery optimization. The company is initially applying to the FDA for approval of its three proprietary drug delivery platforms. Epoladerm™ is a topical aerosol film formulation of diclofenac developed to treat the pain of osteoarthritis. Probudur™ is a long-acting liposomal bupivacaine formulation that is administered as an injection to treat postoperative pain. Envelta™, on the other hand, is an intranasal molecular envelope technology (MET)-based enkephalin formulation developed for the treatment of cancer-related and non-cancer pain and post-traumatic stress disorder (PTSD) under the name PES200. . MET is also used in AnQlar™, a candidate for inhibiting viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired the worldwide rights to VRP324, a nasal pharmaceutical grade cannabidiol candidate for the treatment of epilepsy in children (a rare childhood disease) and adults. For more information, visit www.virpaxpharma.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 of the Private Securities Litigation Reform Act, as amended, including statements regarding proposed clinical trials, product development, clinical and regulatory timelines, the company’s market opportunities, competitive position, potential or anticipated future results of operations, business strategies and potential growth opportunities, and other forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections regarding the industry and markets in which we operate and the current estimates and assumptions made by management.
These statements may be identified by the use of forward-looking words, including, but not limited to, “expect”, “anticipate”, “intend”, “plan”, “believe”, “estimate”, “potential”, “predict”, ” draft”. , “should”, “should” and similar expressions, and the negative of these terms. These statements address future events or our financial results and involve known and unknown risks, uncertainties and other factors, including the potential impact of the coronavirus pandemic and the potential impact of ongoing Efforts to comply with distancing regulations in the operations of the Company, clinical development plans and timelines that may cause actual results, performance or achievements to differ materially from any future results, performance or achievements expressed by the prospect. looking for statements or to be implied. These factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Potential investors are cautioned not to rely on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
The source language in which the original text is published is the official and authorized version. Translations will be included for better understanding. Only the version in the language that was originally published is legally valid. Therefore, compare the translations with the original language version of the publication.
View the original version on businesswire.com: https://www.businesswire.com/news/home/20220315005262/en/
Christopher M. Chipman, CPA
Affinity Growth Advisors